Reuters -- AstraZeneca (AZN.L) has failed to win a summary judgment in a patent battle over its blockbuster cholesterol drug Crestor, denying it early victory in one key aspect of a dispute that will go to full trial in February 2010.
Reuters -- AstraZeneca (AZN.L) has failed to win a summary judgment in a patent battle over its blockbuster cholesterol drug Crestor, denying it early victory in one key aspect of a dispute that will go to full trial in February 2010.
